235 related articles for article (PubMed ID: 29471464)
21. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.
Andrews N; McMenamin J; Durnall H; Ellis J; Lackenby A; Robertson C; von Wissmann B; Cottrell S; Smyth B; Moore C; Gunson R; Zambon M; Fleming D; Pebody R
Euro Surveill; 2014 Jul; 19(27):5-13. PubMed ID: 25033051
[TBL] [Abstract][Full Text] [Related]
22. Genetic and antigenic characterization of hemagglutinin of influenza A/H3N2 virus from the 2015 season in Thailand.
Tewawong N; Suntronwong N; Vichiwattana P; Vongpunsawad S; Theamboonlers A; Poovorawan Y
Virus Genes; 2016 Oct; 52(5):711-5. PubMed ID: 27146171
[TBL] [Abstract][Full Text] [Related]
23. Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.
DeDiego ML; Anderson CS; Yang H; Holden-Wiltse J; Fitzgerald T; Treanor JJ; Topham DJ
Immunology; 2016 Jun; 148(2):160-73. PubMed ID: 26854888
[TBL] [Abstract][Full Text] [Related]
24. Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada.
Skowronski DM; Leir S; Sabaiduc S; Chambers C; Zou M; Rose C; Olsha R; Dickinson JA; Winter AL; Jassem A; Gubbay JB; Drews SJ; Charest H; Chan T; Hickman R; Bastien N; Li Y; Krajden M; De Serres G
J Infect Dis; 2022 Apr; 225(8):1387-1398. PubMed ID: 32215564
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of seasonal influenza vaccine in Australia, 2015: An epidemiological, antigenic and phylogenetic assessment.
Fielding JE; Levy A; Chilver MB; Deng YM; Regan AK; Grant KA; Stocks NP; Sullivan SG
Vaccine; 2016 Sep; 34(41):4905-4912. PubMed ID: 27577556
[TBL] [Abstract][Full Text] [Related]
26. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.
Skowronski DM; Masaro C; Kwindt TL; Mak A; Petric M; Li Y; Sebastian R; Chong M; Tam T; De Serres G
Vaccine; 2007 Apr; 25(15):2842-51. PubMed ID: 17081662
[TBL] [Abstract][Full Text] [Related]
27. Genetic and antigenic divergence in the influenza A(H3N2) virus circulating between 2016 and 2017 in Thailand.
Suntronwong N; Klinfueng S; Vichiwattana P; Korkong S; Thongmee T; Vongpunsawad S; Poovorawan Y
PLoS One; 2017; 12(12):e0189511. PubMed ID: 29252990
[TBL] [Abstract][Full Text] [Related]
28. Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018-2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin.
Wang W; Alvarado-Facundo E; Vassell R; Collins L; Colombo RE; Ganesan A; Geaney C; Hrncir D; Lalani T; Markelz AE; Maves RC; McClenathan B; Mende K; Richard SA; Schofield C; Seshadri S; Spooner C; Utz GC; Warkentien TE; Levine M; Coles CL; Burgess TH; Eichelberger M; Weiss CD
Clin Infect Dis; 2021 Dec; 73(11):e4312-e4320. PubMed ID: 32898271
[TBL] [Abstract][Full Text] [Related]
29. Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications for Seasonal Vaccine Strain Selection and Vaccine Performance.
Kosikova M; Li L; Radvak P; Ye Z; Wan XF; Xie H
Clin Infect Dis; 2018 Oct; 67(10):1523-1532. PubMed ID: 29672713
[TBL] [Abstract][Full Text] [Related]
30. The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.
Petrie JG; Malosh RE; Cheng CK; Ohmit SE; Martin ET; Johnson E; Truscon R; Eichelberger MC; Gubareva LV; Fry AM; Monto AS
Clin Infect Dis; 2017 Oct; 65(10):1644-1651. PubMed ID: 29020179
[TBL] [Abstract][Full Text] [Related]
31. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination.
Liu F; Gross FL; Jefferson SN; Holiday C; Bai Y; Wang L; Zhou B; Levine MZ
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690218
[TBL] [Abstract][Full Text] [Related]
32. Ιnfluenza A(H3N2) genetic variants in vaccinated patients in northern Greece.
Melidou A; Gioula G; Exindari M; Ioannou E; Gkolfinopoulou K; Georgakopoulou T; Tsiodras S; Papa A
J Clin Virol; 2017 Sep; 94():29-32. PubMed ID: 28734139
[TBL] [Abstract][Full Text] [Related]
33. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.
Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay J; Fonseca K; Charest H; Krajden M; Petric M; Mahmud SM; Van Caeseele P; Bastien N; Eshaghi A; Li Y
J Infect Dis; 2015 Sep; 212(5):726-39. PubMed ID: 25784728
[TBL] [Abstract][Full Text] [Related]
34. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Apr; 57(15):393-8. PubMed ID: 18418344
[TBL] [Abstract][Full Text] [Related]
35. A(H3N2) antigenic variation of influenza is associated with low vaccine efficacy in the early 2018 influenza season in Mexico City.
Hernández-Hernández VA; Higuera-Iglesias AL; Palma-Cortes G; Tapia-Trejo D; Ávila-Ríos S; González-Fernández RR; Pérez-Moreno LÁ; Zuñiga-Ramos JA; Guadarrama-Pérez C; Sandoval-Gutiérrez JL; Cabello-Gutiérrez C
Int J Infect Dis; 2022 Dec; 125():114-119. PubMed ID: 36283676
[TBL] [Abstract][Full Text] [Related]
36. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.
de Jong JC; Beyer WE; Palache AM; Rimmelzwaan GF; Osterhaus AD
J Med Virol; 2000 May; 61(1):94-9. PubMed ID: 10745239
[TBL] [Abstract][Full Text] [Related]
37. Effect of seasonal vaccination on the selection of influenza A/H3N2 epidemic variants.
Chong Y; Ikematsu H
Vaccine; 2017 Jan; 35(2):255-263. PubMed ID: 27919631
[TBL] [Abstract][Full Text] [Related]
38. The 2015-2016 influenza epidemic in Beijing, China: Unlike elsewhere, circulation of influenza A(H3N2) with moderate vaccine effectiveness.
Zhang L; Pan Y; Hackert V; van der Hoek W; Meijer A; Krafft T; Yang P; Wang Q
Vaccine; 2018 Aug; 36(33):4993-5001. PubMed ID: 30017144
[TBL] [Abstract][Full Text] [Related]
39. Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.
Camilloni B; Basileo M; Menculini G; Tozzi P; Iorio AM
Adv Exp Med Biol; 2016; 897():45-53. PubMed ID: 26577530
[TBL] [Abstract][Full Text] [Related]
40. Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016-2017 and 2017-2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
Martin ET; Cheng C; Petrie JG; Alyanak E; Gaglani M; Middleton DB; Ghamande S; Silveira FP; Murthy K; Zimmerman RK; Monto AS; Trabue C; Talbot HK; Ferdinands JM;
J Infect Dis; 2021 Jun; 223(12):2062-2071. PubMed ID: 33140094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
